PMID- 24692815
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140402
LR  - 20211021
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 69
IP  - 5
DP  - 2008 Oct
TI  - Kanglaite injection plus chemotherapy versus chemotherapy alone for non-small 
      cell lung cancer patients: A systematic review and meta-analysis.
PG  - 381-411
LID - 10.1016/j.curtheres.2008.10.004 [doi]
AB  - BACKGROUND: Kanglaite (KLT) is a botanically sourced, molecularly targeted agent 
      that is prepared as a microemulsion for IV use. The active substance is extracted 
      from the herb Semen coicis. OBJECTIVE: The aim of this study was to evaluate the 
      effectiveness and tolerability of KLT injection in patients with primary 
      non-small cell lung cancer (NSCLC). METHODS: We electronically searched the 
      literature of the China National Knowledge Infrastructure (Chinese language, 
      1979-March 2008), CBMdisc (Chinese, 1978-March 2008), The Cochrane Library 
      (English, Issue 4, 2007), MEDLINE (English, 1966-March 2008), and EMBASE 
      (English, 1984-March 2008), and manually searched 20 Chinese-language oncology 
      journals to identify randomized controlled trials (RCTs) of KLT injection plus 
      chemotherapy versus chemotherapy alone, regardless of their having been published 
      or not, blinding, duration of treatment, or duration of follow-up. The quality of 
      the included trials was assessed using the method recommended by The Cochrane 
      Collaboration. The studies were assigned to 1 of the following 3 categories: A = 
      all quality criteria met, low risk of bias; B = >/=1 of the quality criteria only 
      partially met, moderate risk of bias; or C = >/=1 of the quality criteria not met, 
      high risk of bias. If heterogeneity existed among subgroups, then overall results 
      were calculated based on a random-effects model; otherwise, a fixed-effects model 
      was used. RESULTS: Electronic database searches yielded 596 citations. A title 
      review eliminated 377 manuscripts; 219 citations were marked for further 
      evaluation. Finally, we identified 26 trials that met the inclusion and exclusion 
      criteria. The 26 RCTs included in this meta-analysis included 2209 patients with 
      NSCLC; no study was graded A, 9 were graded B, and 17 were graded C. The sample 
      size of each trial varied from 40 to 305 patients; none of the trials had 
      precalculated sample sizes. Pooled analyses performed using both fixed- and 
      random-effects models revealed that compared with chemotherapy alone, KLT 
      injection plus chemotherapy improved the response rate (relative risk [RR], 1.34; 
      95% CI, 1.19-1.51 and RR, 1.35; 95% CI, 1.20-1.51, respectively) and quality of 
      life as measured by an increase >/=10 points in the Karnofsky Performance Status 
      score (RR, 2.05; 95% CI, 1.60-2.64). KLT injection plus chemotherapy was 
      associated with improvement in the symptoms of cough, dyspnea, chest pain, 
      fatigue, and anorexia. KLT injection plus chemotherapy was also associated with 
      significant reduction in the incidence of the following adverse events (AEs) 
      based on the fixed and random effects models, respectively: grade II to IV 
      leukopenia (RR, 0.29; 95% CI, 0.22-0.39 and RR, 0.33; 95% CI, 0.22-0.48), anemia 
      (RR, 0.54; 95% CI, 0.42-0.70 and RR, 0.55; 95% CI, 0.40-0.76), thrombocytopenia 
      (RR, 0.39; 95% CI, 0.21-0.71 and RR, 0.40; 95% CI, 0.21-0.78), nausea and 
      vomiting (RR, 0.44; 95% CI, 0.34-0.57 and RR, 0.44; 95% CI, 0.35-0.57), phlebitis 
      (RR, 3.44; 95% Cl, 1.30-9.15 and RR, 3.38; 95% CI, 1.28-8.89), and hepatic 
      dysfunction (RR, 0.44; 95% CI, 0.15-1.35 and RR, 0.44; 95% CI, 0.24-0.81). 
      CONCLUSION: This meta-analysis found that KLT injection in combination with 
      chemotherapy was associated with improved response rate, quality of life, and 
      symptoms, and a reduced incidence of AEs compared with chemotherapy alone in 
      patients with NSCLC. These findings should be viewed with caution because of the 
      low quality of the included trials.
FAU - Liu, Xuemei
AU  - Liu X
AD  - Chinese Cochrane/Evidence-Based Medicine Center, Chinese Journal of 
      Evidence-Based Medicine, Periodical Press of West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Xu, Feng
AU  - Xu F
AD  - Department of Oncology, Periodical Press of West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Wang, Gang
AU  - Wang G
AD  - Department of Integrated Chinese and Western Medicine, West China Hospital of 
      Sichuan University, Chengdu, China.
FAU - Diao, Xiang
AU  - Diao X
AD  - Chinese Journal of Evidence-Based Medicine, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Li, Youping
AU  - Li Y
AD  - Chinese Cochrane/Evidence-Based Medicine Center, Chinese Journal of 
      Evidence-Based Medicine, Periodical Press of West China Hospital of Sichuan 
      University, Chengdu, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC3969920
OTO - NOTNLM
OT  - kanglaite injection
OT  - non-small cell lung cancer
OT  - systematic review
EDAT- 2008/10/01 00:00
MHDA- 2008/10/01 00:01
PMCR- 2008/10/01
CRDT- 2014/04/03 06:00
PHST- 2014/04/03 06:00 [entrez]
PHST- 2008/10/01 00:00 [pubmed]
PHST- 2008/10/01 00:01 [medline]
PHST- 2008/10/01 00:00 [pmc-release]
AID - S0011-393X(08)00096-9 [pii]
AID - 10.1016/j.curtheres.2008.10.004 [doi]
PST - ppublish
SO  - Curr Ther Res Clin Exp. 2008 Oct;69(5):381-411. doi: 
      10.1016/j.curtheres.2008.10.004.